RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$58.41
−0.88%Year over year
Reported trailing growth
- Revenue
- +10.0%
- EBITDA
- -11.1%
- EBIT
- -14.1%
- EPS
- +3.3%
- Free cash flow
- +23.7%
- Operating cash flow
- +23.7%
Forward estimates
Based on analyst estimates
- Revenue
- +35.8%
- EBITDA
- +113.5%
- EPS
- +93.3%
Three-year CAGR
- Revenue
- +2.1%
- EBITDA
- +56.9%
- EBIT
- +71.9%
- Net income
- +162.1%
- EPS
- +187.7%
- Free cash flow
- +5.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026